Genomic and MRD Data for 29 ESCC Patients in Neoadjuvant Chemoimmunotherapy Study

29 stage II-III esophageal squamous cell carcinoma patients were prospectively enrolled in a study of neoadjuvant chemoimmunotherapy. Baseline tumor tissues were analyzed via 437-gene targeted sequencing, and serial plasma samples were profiled using a 2365-gene panel for molecular residual disease monitoring. The dataset, authored by Dijian Shen and last updated in April 2026, associates genomic features and MRD status with major pathological response.

Use Cases

• Predicting major pathological response based on baseline NOTCH1 mutation status mentioned in the description
• Evaluating the predictive power of post-treatment molecular residual disease status for treatment outcomes
• Analyzing the association between chromosomal instability score and pathological response
• Building integrated prediction models combining genomic alterations and dynamic ctDNA monitoring data

Strengths

• Data is from a prospective clinical study of 29 patients, providing a controlled research context.
• Genomic profiling used a 437-gene panel for baseline tissue and a 2365-gene panel for plasma MRD monitoring.
• The study achieved a high predictive AUC of 0.954 for major pathological response using an integrated model.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (13.1 KB), reflecting a limited cohort of 29 patients.

Provenance

Source

figshare, authored by Dijian Shen.

Collection Method

Prospective clinical study with genomic sequencing of tumor tissue and plasma samples.

Freshness

Last updated 2026-04-30 05:39:52; freshness should be verified.